SpectrumX fires the starting pistol on £50mln London IPO
It is understood the group has submitted its prospectus to the London Stock Exchange ahead of a float in late spring
Sector
Health
1090 stories · page 37 of 55
Wellbeing Digital Sciences appoints Najla Guthrie as CEO effective March 31
Guthrie is the current Chief Research Officer and president of KGK Science Inc and has led it to become a leading North American contract research organization that primarily provides high-quality clinical research trials with a focus on th
Pathway Health to acquire assets of National Cannabinoid Clinics; transaction expected to close in 2Q 2022
"The potential tuck-in acquisition of NCC's operating assets will continue to expand the number of patients across Canada that have access to our products and services," said Ken Yoon, CEO of Pathway Health
NA Proactive news snapshot: MAS Gold, ION Energy, Kontrol Technologies, Snowline Gold UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Wellbeing Digital Sciences says IRP Health subsidiary wins approval from Veterans Affairs Canada for Reactivation program
"This brings us one step closer to achieving our goal of a Canadian wide network of purpose-built programs for veterans and first responders who desperately need access to care," said Wellbeing interim CEO Adam Deffett
Braxia Scientific generates double-digit year-over-year revenue increase in its fiscal 3Q 2022
For the three-month period ending December 31, 2021, the company recorded revenue of $324,902, reflecting a 13.3% increase from the year-ago quarter thanks to sales of ketamine-infusion treatments
Wellbeing Digital Sciences delivers first IV ketamine treatment under new in-patient program
“The company has always wanted to make a positive and significant impact on mental health and this brings us one step closer,” Wellbeing interim CEO Adam Deffett said
Pathway Health adds more physicians to its flagship Silver Pain Centre in Toronto
The company said it had also added a second fluoroscopy suite at Silver that will allow the company’s pain specialists to treat more patients using “real-time diagnostic imaging, allowing for more precise treatments”
Roquefort Therapeutics: Pioneering approach to cancer drawing interest from big pharma and private eq
Roquefort bought LYRAMID in December LYRAMID business is a pioneer in midkine inhibition When overexpressed, midkine is linked with a host of diseases
Irwin Naturals initiates rollup of psychedelic mental health clinics
CEO Irwin noted that the company sees itself as gaining the national brand first-mover advantage and will be leveraging its brand equity and status as a cult brand to expand rapidly as society embraces the psychedelic mental health revoluti
Wellteq Digital Health says study shows that its technology can improve employees' sleep
The results of the study come from 13 countries, eight enterprise markets and 529 participants and "demonstrate a substantial and clinically meaningful improvement in nightly sleep duration achieved by 59% of employee participants", the com
Wellbeing Digital Sciences says its subsidiary KGK Science expects significant growth in 2022
KGK is currently working on psychedelic drug projects with eight distinct clients, managing four clinical trials including a Phase 1 study of a proprietary psilocybin extract in healthy adults
Braxia Scientific says it continues psychedelic-based clinical research trials to support future drug development
Braxia Scientific's researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and its wholly-owned subsidiary has established a growing database with key clinical outcomes for an ongoing clinical trial
Wellbeing says its subsidiary KGK Science partners with Nova Mentis for developing psychedelic drug portfolio
Both companies plan to jointly submit a clinical trial application to Health Canada for a Phase 2A clinical study evaluating psilocybin microdose therapy for fragile X syndrome
Britain needs 6,000 more volunteers to take Merck’s COVID-19 pill mainstream
The government is looking for the best way to roll out the pill in a largely vaccinated population
KetamineOne changes name to Wellbeing Digital Sciences
“Wellbeing Digital Sciences is a name that acknowledges each one of our three core pillars: clinic-based treatments, contract research, and health technology,” said Adam Deffett, interim CEO of Wellbeing
Revive Therapeutics updates on several psilocybin initiatives to be completed in 2022
The firm is embarking on its first clinical study evaluating psilocybin in the treatment of methamphetamine use disorder and advancing the development of an oral psilocybin thin file strip and psilocybin microneedle patch
Ketamine One becomes exclusive provider of ketamine treatment to Victoria Wellness
“This exclusive agreement with VW is a meaningful opportunity to help even more veterans and other members of the general public who are battling daily with anxiety, depression and PTSD,” said Ketamine One chief operating offer Steven Ingle
Universal Ibogaine introduces its CRO partners ahead of potential clinical trial for opioid use disorder in Canada
The company is currently working with its contract research organization (CRO) partners to finalize the study's design ahead of an expected pre-clinical trial application with Health Canada